Right From Your Office
Helping You Deliver Breakthrough Cancer Care
FDA-approved therapy. Full clinical oversight. Zero hospital stays.
FDA Expands Pluvicto® Approval — More Patients Eligible, Sooner
On March 28, 2025, the FDA expanded approval of Pluvicto® for patients with PSMA-positive mCRPC after just one ARPI — even before chemotherapy.
This update nearly triples the number of patients eligible for Lu-177 PSMA therapy.
RadiantPath brings this breakthrough treatment directly to your practice — accelerating access, reducing delays, and expanding care for those who need it most.
- 59% reduction in risk of progression or death
- 2x median rPFS (11.6 vs. 5.6 months vs. ARPI)
- Delivered in-office by NRC-licensed care teams
- Integrated with your EMR and care protocols
Pluvicto® in Action: Clinical Imaging Results
This PSMA PET scan shows the real-world effect of Pluvicto® treatment in a patient with metastatic prostate cancer.
The left scan reveals extensive cancer activity before therapy.
The right scan, taken after Lu-177 PSMA treatment, shows significant reduction in disease burden.
RadiantPath brings this breakthrough directly to your practice, making targeted therapy more accessible, streamlined, and effective.
Redefining Access to Lu-177 PSMA Therapy
RadiantPath delivers FDA-approved radioligand therapy (Pluvicto®) for metastatic prostate cancer via licensed mobile infusion units, reaching patients in their communities.
We partner with urologists and oncologists to facilitate and streamline care.
Clinical Challenge
Prostate cancer patients deserve more than the wait!
- 50% of patients with mCRPC don’t survive to a second-line therapy
- Many eligible for Pluvicto can’t access distant RLT centers
- Traditional care pathways delay use of effective options
- Clinicians lack logistical support for RLT coordination
Clinical Integration, Simplified
RadiantPath partners with community-based providers to deliver targeted radioligand therapy, directly in-office eliminating the need for hospital referrals while maintaining full clinical oversight.
- Mobile Lu-177 Therapy Delivery
- Pluvicto® is now approved for pre-chemo use in PSMA-positive mCRPC. RadiantPath delivers therapy on-site via licensed nuclear medicine professionals and NRC-compliant protocols.
- Molecular Imaging Review & Eligibility
- We support PSMA PET/CT access, interpret results, and assess Pluvicto® eligibility. RadiantPath helps your team screen and refer with confidence.
- Documentation & Reporting
- From prior auth to final progress notes, we provide full documentation tailored to your EMR workflow — including coding support and follow-up plans.
- Turnkey Clinical Partnership
- Our team handles coordination, therapy administration, compliance, and reporting — so your clinic expands treatment access without increasing workload.
—NOW ACCEPTING REFERRALS —
Let's Expand Access Together
Contact us to request a referral packet, clinical overview, or scheduling availability for your practice. Let’s bring theranostics where it’s needed most.
“Healing happens best when we do it together.”